抗高血压药物阿姆洛迪平酸显示出减轻糖尿病外围神经病变的潜力
Yuxi Wei1, Yujie Huang1, Runzhi Huang2
1Jiangsu Key Laboratory of Drug Target and Drug for Degenerative Diseases, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Diabetes
|February 28, 2025
概括
阿姆洛迪平贝西酸盐 (AB) 通过激活G蛋白结合受体40 (GPR40) 来治疗糖尿病外围神经病变 (DPN) 是有前途的. 这种药物可以缓解DPN模型中的神经损伤和功能障碍.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病外围神经病变 (DPN) 是一种常见的,使人衰弱的糖尿病并发症,没有有效的治疗方法.
- 在DPN患者和糖尿病小鼠模型的外周神经中观察到降低的G蛋白结合受体40 (GPR40) 蛋白水平.
- 目前对DPN的治疗选择有限,需要新的治疗策略.
研究的目的:
- 调查阿姆洛迪平贝西酸盐 (AB) 的治疗潜力,这是已知的GPR40激动剂,用于治疗DPN.
- 阐明AB改善DPN病理的潜在分子机制.
- 在DPN的临床前模型中评估AB的疗效.
主要方法:
- 在DPN患者和糖尿病小鼠 (1型和2型) 的坐骨神经中评估了GPR40蛋白水平.
- 使用腺相关病毒8-GPR40-RNAi生成了具有GPR40淘汰的DPN小鼠模型.
- 机理学研究涉及分析DPN小鼠和人类原发性施万细胞中的炎症和线粒体通路 (GPR40/β-arrestin2/NLRP3和GPR40/LKB1/AMPK/SIRT1/PGC-1α) 和细胞间交叉.
主要成果:
- 在DPN患者和糖尿病小鼠的外周神经中,GPR40蛋白水平显著下降.
- 阿姆洛迪平酸盐 (AB) 治疗缓解了类似DPN的病态,包括神经损伤,髓破坏,血管损伤和神经元外生损伤.
- 在机械上,AB通过GPR40/β-arrestin2/NLRP3通路减轻了炎症,并通过GPR40/LKB1/AMPK/SIRT1/PGC-1α通路改善了线粒体功能.
- 在 DPN 模型中,AB 抑制了 Schwann 细胞,内皮细胞和背部根结质神经元之间的有害交谈.
结论:
- 阿姆洛迪平酸盐 (AB) 通过作为GPR40激动剂,显示出糖尿病外围神经病变 (DPN) 的显著治疗潜力.
- 通过调节炎症和线粒体通路并改善神经元支细胞功能,AB有效地改善了关键的DPN病理.
- 这些发现表明,AB可能是DPN的可行治疗选择,特别是在后期阶段.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
434
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
434
01:16Antihypertensive Drugs: Action of Diuretics
610
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
610
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
433
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
433
01:23Antihypertensive Drugs: Vasodilators
455
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
455
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
437
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
437